Samsung Biologics Q1 Operating Profit Reaches 580.8 Billion Won, Up 35% Year-on-Year

by Jeong Donghoon

Published 22 Apr.2026 16:02(KST)

Updated 22 Apr.2026 16:21(KST)

Sales Reach 1.2571 Trillion Won... Up 26% Year-on-Year

Samsung Biologics announced in a disclosure on April 22 that it posted KRW 1.2571 trillion in revenue and KRW 580.8 billion in operating profit for the first quarter of this year. Thanks to the full-capacity operation of Plants 1 through 4, revenue increased by 26% (KRW 257.6 billion) and operating profit by 35% (KRW 150.6 billion) compared to the same period last year.

Exterior view of Samsung Biologics Plant 4. Samsung Biologics

The company maintained its annual revenue growth guidance at 15-20%, as presented in January. This reflects the full-scale operation of Plants 1 through 4, as well as the ramp-up phase (increased utilization) of Plant 5. The revenue contribution from the recently acquired Rockville, Maryland plant in the United States will be announced after it is reflected in future results. As of the end of the first quarter, Samsung Biologics’ assets stood at KRW 11.995 trillion, equity at KRW 7.9228 trillion, and liabilities at KRW 4.0722 trillion. The company’s debt ratio was 51.4%, and its borrowing ratio was 11.6%, maintaining a stable financial structure.

In terms of business operations, since its founding, Samsung Biologics has secured 112 contract manufacturing (CMO) deals and 169 contract development (CDO) deals, with a cumulative order value of USD 21.4 billion (approximately KRW 31.64 trillion). In particular, with the completion of the acquisition of the Rockville manufacturing facility in the United States at the end of March, the company has established a dual production system linking Songdo, Korea, and Rockville, U.S., allowing it to respond more closely to global clients.

Additionally, by internalizing master cell bank (MCB) production and vector manufacturing services, Samsung Biologics has established an end-to-end service system capable of completing everything from vector construction to Investigational New Drug (IND) application submission within nine months. The company has also secured flexible manufacturing capabilities based on the Coalition for Epidemic Preparedness Innovations (CEPI) network.

For future growth, Samsung Biologics has agreed to collaborate with Eli Lilly in establishing a domestic base for ‘Lilly Gateway Labs (LGL),’ the open innovation program of the global pharmaceutical company, in Songdo, Incheon. This marks the first case of a foreign pharmaceutical company entering Korea through collaboration with a local firm. In terms of sustainable management, Samsung Biologics received the highest ‘Platinum’ rating from global assessment agency EcoVadis. The company is also strengthening ESG management in its supply chain through initiatives such as signing its first ESG (Environmental, Social, and Governance) contract with a partner and obtaining third-party verification of its product carbon footprint calculation system.